Observational analysis reports adverse events in patients receiving camizestrant with CDK4/6 inhibitors, indicating treatment safety considerations.
AEs leading to dose reduction or discontinuation in patients treated with camizestrant 75, 150, or 300 mg combined with either abemaciclib, palbociclib, or ribociclib. Description data are presented as number and % of patients. N, number; NA, not applicable.
No takes yet. Share an insight, caveat, or question.
Baird et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: